Evaluation of the antiviral activity of benzydamine hydrochloride and its finished dosage form Tantum® Verde against herpes simplex virus types 1 and 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Herpes simplex viruses (HSV) types 1 and 2 are widespread in the human population and can cause a number of conditions in the human body, ranging from asymptomatic to severe generalized forms of the disease. Objective. Evaluation of the antiviral activity of benzydamine hydrochloride in an experimental model of herpesvirus infection in vitro. Methods. Evaluation of the antiviral activity of benzydamine hydrochloride was carried out on a model of herpesvirus infection caused by HSV types 1 and 2 in a VERO-B cell culture using virological and statistical research methods. Results. It was found that the use of benzydamine hydrochloride according to the therapeutic scheme (one hour after the adsorption of the virus) led to a decrease in the infectious activity of HSV-1 by 1.5-3.6 lg TCD50, and the infectious activity of HSV-2 by 1.5-3.06 lg TCD50 compared with the activity of control test viruses. The maximum statistically significant inhibitory effect in relation to HSV-1 and -2 was detected when using the drug at a concentration of 62.5 pg/ml; the inhibition coefficient in relation to HSV-1 and -2 was 60 and 54.45%, respectively. Conclusion. As a result of the study, it was established that benzydamine hydrochloride has therapeutic activity against herpesvirus infection caused by widespread pathogens - HSV-1 and -2 in vitro, during the early period of viral replication. The antiviral activity of the drug is dose-dependent.

Full Text

Restricted Access

About the authors

Lyudmila M. Alimbarova

Gamaleya National Research Center for Epidemiology and Microbiology

Email: virology@mail.ru
Cand. Sci. (Med.) Associate Professor, Leading Researcher at the Laboratory of Comparative Virology with the Russian Herpes Center 18, Gamaleya str., Moscow 123098, Russian Federation

I. V Kukes

Angelini Pharma Rus LLC

Medical Department Moscow, Russia

References

  1. Герпесвирусные инфекции человека: руководство для врачей». Под ред. Исакова В.А. СПб.: СпецЛит, 2013.
  2. Smith J.S., Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. J Infect Dis. 2002;186(suppl1):S3-S28. doi: 10.1086/343739.
  3. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55:459-72. doi: 10.1128/AAC.00615-10.
  4. Клинические рекомендации - простой герпес (ПГ) у взрослых. КР492, Международная ассоциация специалистов в области инфекций (МАСОИ), МЗ РФ, 2016.
  5. Fanaki N.H., el-Nakeeb M.A. Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent. J Chemother. 1992;4(6):347-52. Doi: 10. 1080/1120009X.1992.11739190.
  6. Quane P.A., Graham G.G., Ziegler J.B. Pharmacology of benzydamine. Inflammopharmacology. 1998;6(2):95-107. doi: 10.1007/s10787-998-0026-0.
  7. Reed L., Muench H. A simple method of estimating 50% endpoints. Amer J Hygiene. 1938; 27:493-97.
  8. Миронов А.Н., Бунатян Н.Д., Васильев А.Н. и др. Руководство по проведению доклинических исследований лекарственных средств. Часть 1. М.: Гриф и К, 2012. 944 с.
  9. De Clerg E., Descamhs J., Verhelst G., et al. Comparitive efficiecy of antiherpes drugs against different strains of herpes simplex virus. J Inf Dis. 1980;141(5):563-74. doi: 10.1093/infdis/141.5.563.
  10. Cotarelo M., Catalan P., Sanchez-Carrillo C., et al. Cytopathic effect inhibition assay for determining the in vitro susceptibility of herpes simplex virus to antiviral agents. J Antimicrob Chemother. 1999;44:705-8. doi: 10.1093/jac/44.5.705.
  11. Клинические рекомендации - острый тонзиллофарингит. КР306, Национальная медицинская ассоциация оториноларингологов, МЗ РФ, 2016.
  12. Alvarez D.M., Duarte L.F., Corrales N., et al. Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts. Antiviral Res. 2020;179:104818. doi: 10.1016/j.antiviral.2020.104818.
  13. Баринский И.Ф., Алимбарова Л.М., Кириченко И.М. Изучение in vitro антивирусных свойств Мирамистина® в отношении вируса простого герпеса типов 1 и 2. Поликлиника. 2011;3:98-9.
  14. Дерябин П.Г, Галегов Г.А., Андронова В.А., Ботиков А.Г Изучение противовирусных свойств препарата «Гексорал» in vitro в отношении ряда вирусов, вызывающих острые респираторные инфекции и герпес. Бюллетень экспериментальной биологии и медицины. 2015;9:339-42.
  15. Sironi M., Massimiliano L., Transidico P., et al. Differential effect of benzydamine on pro-versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist. Int J Clin Lab Res. 2000;30(1):17-9. doi: 10.1007/s005990070028.
  16. Слукин П.В., Фурсова Н.К., Брико Н.И. Антибактериальная активность бензидамина гидрохлорида против клинических изолятов бактерий, выделенных от людей в России и Испании. Эпидемиология и вакцинопрофилактика. 2018;17(6):11-8. Doi: https://doi.org/10.31631/2073-3046-2018-17-11-18

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies